Barcelona, Oct 25 (EFE).- Araclon Biotech, a Grifols Group company, has assured this Wednesday that the phase 2 trial of ABvac40, which is the first Spanish vaccine against Alzheimer’s, presents positive results in the treatment of patients with this disease in its initial phase.
Araclon Biotech presented these results at the Clinical Trials on Alzheimer’s Disease conference, in which it assured that treatment with ABvac40 slowed the progression of the disease “by up to 38%” compared to placebo, Grifols reported this Wednesday.
In phase II of a trial, the effectiveness of a drug or treatment is evaluated in a group of patients with a specific disease and additional data on its safety are obtained.
Always according to Araclon Biotech, the results show that their vaccine demonstrated “a favorable safety profile, provoked a robust immune response against the Aβ40 peptide, and demonstrated some potential cognitive benefits in patients with early-stage Alzheimer’s.”
ABvac40 is uniquely designed to target the C-terminus of the Aβ40 peptide and is believed to prevent harmful reactions and avoid the immune triggers responsible for meningoencephalitis, a complication seen in previous Alzheimer’s vaccines.
New research suggests that the Αβ40 peptide plays a role in cerebral amyloid angiopathy (CAA), a condition highly prevalent among the growing number of Alzheimer’s patients.
The number of Alzheimer’s patients is expected to double by 2050 in the United States alone, compared to 6.7 million in 2023 in that country.
Grifols assures that although the trial “did not have the necessary power to determine efficacy on neuropsychological scales,” the group treated with ABvac40 “showed a reduction of up to 38% in disease progression.”
This phase 2 trial has been carried out in 23 centers in the EU and has served to investigate the safety, tolerability and immunogenicity of repeated subcutaneous injections of this vaccine in patients with amnestic mild cognitive impairment or very mild Alzheimer’s disease. A total of 134 patients participated in the study.
The CEO of Araclon, José Terencio, highlighted the “robust immune response with some significant reduction in disease progression” that this trial demonstrates.
For her part, Dr. Mercè Boada Rovira, co-founder and medical director of the Ace Alzheimer Center in Barcelona and principal investigator of the study, commented that “by specifically targeting the Aβ40 peptide, the vaccine is taking advantage of a central mechanism that is believed to drive the cognitive impairment with the potential to alter the course of the disease.” EFE
jd/rq
2023-10-25 10:05:00
#Grifols #presents #positive #results #phase #vaccine #Alzheimers #Vanguardia
